We are proud to share that Dr. Art Hsing-Mao Chu, CEO of T-E Meds, was invited to present at the BIO Asia–Taiwan 2024 conference on July 24-28,2024. Dr. Chu’s presentation, titled “Drug Bundle-Based ADC Platform: Achieving Site-Specific Conjugation, DAR of 8 or 12, and Dual Payloads,” highlighted our innovative technology.
The talk emphasized how our novel ADC platform streamlines the CMC process and generates high-DAR, dual-payload ADCs with superior efficacy and outstanding stability. These advancements position us at the forefront of therapeutic development.
We welcome partnerships to further advance these groundbreaking technologies and transform patient care. Let’s innovate together!
Please read more at:
https://news.gbimonthly.com/tw/article/show.php?num=69744&range=news